Skip to main content

Table 4 Summary of treatment-emergent AEs

From: A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma

  Placebo (n = 166) Grass AIT (n = 163)
  N (%)* Events N (%)* Events
All 101 (61) 258 121 (74) 454
Causality     
  Probably related 11 (7) 23 73 (45) 184
  Possibly related 13 (8) 29 20 (12) 29
  Unlikely related 93 (56) 206 95 (58) 241
Severity     
  Mild 70 (42) 146 100 (61) 268
  Moderate 57 (34) 94 75 (46) 156
  Severe 14 (8) 18 20 (12) 30
  1. *Represents all subjects experiencing AE of each causality/severity; each subject could experience AEs in multiple categories of causality/severity. AE Adverse event, AIT Allergy immunotherapy tablet.